Cognitive Enhancement Therapy for a Model of Down Syndrome

Science Translational Medicine

Volumn 1, Issue 7, 2009, Pages

  Wiseman, Frances K ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

NORADRENALIN;

ANIMAL; COGNITION; DISEASE MODEL; DOWN SYNDROME; HUMAN; MOUSE; NOTE; PATHOPHYSIOLOGY; PHYSIOLOGY; PSYCHOLOGICAL ASPECT; SIGNAL TRANSDUCTION; THEORETICAL MODEL;

ANIMALS; COGNITION; DISEASE MODELS, ANIMAL; DOWN SYNDROME; HUMANS; MICE; MODELS, THEORETICAL; NOREPINEPHRINE; SIGNAL TRANSDUCTION;

EID: 77951568674     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.3000449     Document Type: Review

References (35)

1. F. K. Wiseman, K. A. Alford, V. L. Tybulewicz, E. M. Fisher, Down syndrome - recent progress and future prospects. Hum. Mol. Genet. 18 (R1), R75-R83 (2009).
2. A. Salehi, M. Faizi, D. Colas, J. Valletta, J. Laguna, R. Takimoto-Kimura, A. Kleschevnikov, S. L. Wagner, P. Aisen, M. Shamloo, W. C. Mobley, Restoration of norepinephrine-modulated contextual memory in a mouse model of Down syndrome. Sci. Transl. Med. 1, 7ra17 (2009).
3. K. Gardiner, A. C. Costa, The proteins of human chromosome 21. Am. J. Med. Genet. C. Semin. Med. Genet. 142C, 196-205 (2006).
4. E. Aït Yahya-Graison, J. Aubert, L. Dauphinot, I. Rivals, M. Prieur, G. Golfier, J. Rossier, L. Personnaz, N. Creau, H. Bléhaut, S. Robin, J. M. Delabar, M. C. Potier, Classification of human chromosome 21 gene-expression variations in Down syndrome: Impact on disease phenotypes. Am. J. Hum. Genet. 81, 475-491 (2007).
5. P. Prandini, S. Deutsch, R. Lyle, M. Gagnebin, C. Delucinge Vivier, M. Delorenzi, C. Gehrig, P. Descombes, S. Sherman, F. Dagna Bricarelli, C. Baldo, A. Novelli, B. Dallapiccola, S. E. Antonarakis, Natural gene-expression variation in Down syndrome modulates the outcome of gene-dosage imbalance. Am. J. Hum. Genet. 81, 252-263 (2007).
6. R. H. Reeves, N. G. Irving, T. H. Moran, A. Wohn, C. Kitt, S. S. Sisodia, C. Schmidt, R. T. Bronson, M. T. Davisson, A mouse model for Down syndrome exhibits learning and behaviour deficits. Nat. Genet. 11, 177-184 (1995).
7. D. M. Mann, M. C. Royston, C. R. Ravindra, Some morphometric observations on the brains of patients with Down's syndrome: Their relationship to age and dementia. J. Neurol. Sci. 99, 153-164 (1990).
8. S. J. Sara, The locus coeruleus and noradrenergic modulation of cognition. Nat. Rev. Neurosci. 10, 211-223 (2009).
9. H. Tohgi, T. Abe, S. Takahashi, The effects of L-threo-3,4- dihydroxyphenylserine on the total norepinephrine and dopamine concentrations in the cerebrospinal fluid and freezing gait in parkinsonian patients. J. Neural Transm. Park. Dis. Dement. Sect. 5, 27-34 (1993).
10. D. S. Goldstein, L-Dihydroxyphenylserine (L-DOPS): A norepinephrine prodrug. Cardiovasc. Drug Rev. 24, 189-203 (2006).
11. M. E. Bangs, S. Tauscher-Wisniewski, J. Polzer, S. Zhang, N. Acharya, D. Desaiah, P. T. Trzepacz, A. J. Allen, Meta-analysis of suicide-related behavior events in patients treated with atomoxetine. J. Am. Acad. Child Adolesc. Psychiatry 47, 209-218 (2008).
12. A. J. Holland, J. Hon, F. A. Huppert, F. Stevens, Incidence and course of dementia in people with Down's syndrome: Findings from a population-based study. J. Intellect. Disabil. Res. 44, 138-146 (2000).
13. M. P. Janicki, A. J. Dalton, Prevalence of dementia and impact on intellectual disability services. Ment. Retard. 38, 276-288 (2000).
14. P. Johannsen, J. E. Christensen, J. Mai, The prevalence of dementia in Down syndrome. Dementia 7, 221-225 (1996).
15. D. C. German, K. F. Manaye, C. L. White 3rd, D. J. Woodward, D. D. McIntire, W. K. Smith, R. N. Kalaria, D. M. Mann, Disease-specific patterns of locus coeruleus cell loss. Ann. Neurol. 32, 667-676 (1992).
16. C. Zarow, S. A. Lyness, J. A. Mortimer, H. C. Chui, Neuronal loss is greater in the locus coeruleus than nucleus basalis and substantia nigra in Alzheimer and Parkinson diseases. Arch. Neurol. 60, 337-341 (2003).
17. W. J. Hoogendijk, C. W. Pool, D. Troost, E. van Zwieten, D. F. Swaab, Image analyser-assisted morphometry of the locus coeruleus in Alzheimer's disease, Parkinson's disease and amyotrophic lateral sclerosis. Brain 118, 131-143 (1995).
18. J. N. O'Neil, P. R. Mouton, Y. Tizabi, M. A. Ottinger, D. L. Lei, D. K. Ingram, K. F. Manaye, Catecholaminergic neuronal loss in locus coeruleus of aged female dtg APP/PS1 mice. J. Chem. Neuroanat. 34, 102-107 (2007).
19. Y. Liu, M. J. Yoo, A. Savonenko, W. Stirling, D. L. Price, D. R. Borchelt, L. Mamounas, W. E. Lyons, M. E. Blue, M. K. Lee, Amyloid pathology is associated with progressive monoaminergic neurodegeneration in a transgenic mouse model of Alzheimer's disease. J. Neurosci. 28, 13805-13814 (2008).
20. S. Kalinin, V. Gavrilyuk, P. E. Polak, R. Vasser, J. Zhao, M. T. Heneka, D. L. Feinstein, Noradrenaline deficiency in brain increases beta-amyloid plaque burden in an animal model of Alzheimer's disease. Neurobiol. Aging 28, 1206-1214 (2007).
21. E. R. Peskind, D. Wingerson, S. Murray, M. Pascualy, D. J. Dobie, P. Le Corre, R. Le Verge, R. C. Veith, M. A. Raskind, Effects of Alzheimer's disease and normal aging on cerebrospinal fluid norepinephrine responses to yohimbine and clonidine. Arch. Gen. Psychiatry 52, 774-782 (1995).
22. P. Szot, S. S. White, J. L. Greenup, J. B. Leverenz, E. R. Peskind, M. A. Raskind, Compensatory changes in the noradrenergic nervous system in the locus ceruleus and hippocampus of postmortem subjects with Alzheimer's disease and dementia with Lewy bodies. J. Neurosci. 26, 467-478 (2006).
23. A. Salehi, J. D. Delcroix, P. V. Belichenko, K. Zhan, C. Wu, J. S. Valletta, R. Takimoto-Kimura, A. M. Kleschevnikov, K. Sambamurti, P. P. Chung, W. Xia, A. Villar, W. A. Campbell, L. S. Kulnane, R. A. Nixon, B. T. Lamb, C. J. Epstein, G. B. Stokin, L. S. Goldstein, W. C. Mobley, Increased App expression in a mouse model of Down's syndrome disrupts NGF transport and causes cholinergic neuron degeneration. Neuron 51, 29-42 (2006).
24. F. Fernandez, W. Morishita, E. Zuniga, J. Nguyen, M. Blank, R. C. Malenka, C. C. Garner, Pharmacotherapy for cognitive impairment in a mouse model of Down syndrome. Nat. Neurosci. 10, 411-413 (2007).
25. A. M. Kleschevnikov, P. V. Belichenko, A. J. Villar, C. J. Epstein, R. C. Malenka, W. C. Mobley, Hippocampal long-term potentiation suppressed by increased inhibition in the Ts65Dn mouse, a genetic model of Down syndrome. J. Neurosci. 24, 8153-8160 (2004).
26. A. C. Costa, J. J. Scott-McKean, M. R. Stasko, Acute injections of the NMDA receptor antagonist memantine rescue performance deficits of the Ts65Dn mouse model of Down syndrome on a fear conditioning test. Neuropsychopharmacology 33, 1624-1632 (2007).
27. N. Johnson, C. Fahey, B. Chicoine, G. Chong, D. Gitelman, Effects of donepezil on cognitive functioning in Down syndrome. Am. J. Ment. Retard. 108, 367-372 (2003).
28. I. T. Lott, K. Osann, E. Doran, L. Nelson, Down syndrome and Alzheimer disease: Response to donepezil. Arch. Neurol. 59, 1133-1136 (2002).
29. V. P. Prasher, Review of donepezil, rivastigmine, galantamine and memantine for the treatment of dementia in Alzheimer's disease in adults with Down syndrome: Implications for the intellectual disability population. Int. J. Geriatr. Psychiatry 19, 509-515 (2004).
30. G. A. Spiridigliozzi, J. H. Heller, B. G. Crissman, J. A. Sullivan-Saarela, R. Eells, D. Dawson, J. Li, P. S. Kishnani, Preliminary study of the safety and efficacy of donepezil hydrochloride in children with Down syndrome: A clinical report series. Am. J. Med. Genet. A. 143A, 1408-1413 (2007).
31. P. S. Kishnani, B. R. Sommer, B. L. Handen, B. L. Seltzer, G. T. Capone, G. A. Spiridigliozzi, J. H. Heller, S. Richardson, T. McRae, The efficacy, safety, and tolerability of donepezil for the treatment of young adults with Down syndrome. Am. J. Med. Genet. A. 149A, 1641-1654 (2009).
32. J. H. Heller, G. A. Spiridigliozzi, J. A. Sullivan, P. M. Doraiswamy, R. R. Krishnan, P. S. Kishnani, Donepezil for the treatment of language deficits in adults with Down syndrome: A preliminary 24-week open trial. Am. J. Med. Genet. A. 116A, 111-116 (2003).
33. J. H. Heller, G. A. Spiridigliozzi, P. M. Doraiswamy, J. A. Sullivan, B. G. Crissman, P. S. Kishnani, Donepezil effects on language in children with Down syndrome: Results of the first 22-week pilot clinical trial. Am. J. Med. Genet. A. 130A, 325-326 (2004).
34. L. Y. Park-Wyllie, M. M. Mamdani, P. Li, S. S. Gill, A. Laupacis, D. N. Juurlink, C. Brayne, Cholinesterase inhibitors and hospitalization for bradycardia: A population-based study. PLoS Med. 6, e1000157 (2009).
35. D. J. Fidler, L. Nadel, Education and children with Down syndrome: Neuroscience, development, and intervention. Ment. Retard. Dev. Disabil. Res. Rev. 13, 262-271 (2007).